KIT and rheumatoid arthritis: Imatinib suppresses many signaling pathways implicated in RA pathological processes, such as mast cell c-Kit signaling, TNF-α release, macrophage c-Fms activation, cytokine production, and fibroblast PDGFR signaling and proliferation (11).